Stem Cell Therapeutics gets NOL from Health Canada for phase IIa trial in traumatic brain injury patients
Stem Cell Therapeutics Corp. (SCT) announced it has received a No Objection Letter (NOL) from Health Canada for the company supported, investigator-led phase IIa, single centre, open label study to characterize the safety of human Chorionic Gonadotropin (hCG) & Erythropoietin (EPO) in severe traumatic brain injury (TBI) patients .
[Read the full article here]Related News:
Stem Cell Therapeutics Corp. Receives ‘No Objection Letter’ From Health Canada For The Phase IIa Clinical Trial In Traumatic Brain Injury Patients
Stem Cell Therapeutics Corp. Receives ‘No Objection Letter’ From Health Canada for the Phase IIa Clinical Trial in …
BGS Global Hospitals conducts first stem cell transplant for traumatic brain injury